Burzynski Research Institute INC 10-Q quarterly reports

Burzynski Research Institute continues to report net losses and a significant accumulated deficit, remaining dependent on Dr. Burzynski's funding while its Antineoplaston clinical trials remain under full FDA clinical hold.

Burzynski Research Institute reports continued net losses and a significant working capital deficit for Q2 2025, with its clinical trials remaining under full FDA clinical hold.

Burzynski Research Institute, Inc. filed its quarterly report, revealing ongoing net losses, a significant accumulated deficit, and continued reliance on its founder for funding, while its Antineoplaston drug trials remain under a full FDA clinical hold.

Burzynski Research Institute's Q3 2024 financial results reveal a net loss, with research and development expenses increasing and a clinical hold still in effect.

Burzynski Research Institute's latest quarterly report reveals increased operating losses and continued reliance on funding from Dr. Burzynski, while clinical trials remain on hold.

Burzynski Research Institute reported a net loss of $371,332 for the first quarter of 2024, with operations primarily funded by Dr. Burzynski's contributions.

Burzynski Research Institute's Q3 2023 report reveals increased net losses and operating expenses, while the company remains under a full clinical hold by the FDA.